United States Patent 10,945,948 (Loteprednol Etabonate Poloxamer 407 Nanoparticle Ophthalmic Suspension) Scope, Claims, and US Patent Landscape
Executive summary: US patent 10,945,948 claims a topical (eye-drop) method for treating dry eye using an ophthalmic suspension containing loteprednol etabonate–core, poloxamer 407–noncovalently adsorbed coated nanoparticles at ~0.25% w/v loteprednol etabonate, with defined pH (5 < = pH <= ~7), optional benzalkonium chloride, defined surfactant/poloxamer and excipient ranges, and administration four times daily (with dosage variants of 1-2 drops per eye). The claim set is highly specific to composition architecture (nanoparticles + noncovalent poloxamer coating) and tight formulation constraints (core composition wt%, excipient ranges, osmolality targets), which sharply narrows design-around options for competitors using different coating chemistries, different steroid forms, different concentrations, or different dosing schedules.
What is US Patent 10,945,948 claiming for dry eye treatment with loteprednol etabonate?
Core answer: The independent claim is a method-of-treatment claim where the therapeutic act is inseparable from the specific ophthalmic suspension composition and dosing regimen.
Claim 1 (independent) claim anatomy
Claim 1 requires, in combination:
-
Use/route/indication
- Method for treating an eye disorder in a patient in need thereof
- Eye disorder is explicitly dry eye condition
- Administration is topical instillation into an eye
- Formulated as an eye drop
- Four times daily dosing
-
Active and nanoparticle architecture
- Ophthalmic suspension comprises about 0.25% w/v loteprednol etabonate
- Contains a plurality of coated nanoparticles
- Each coated nanoparticle has:
- Core particle comprising loteprednol etabonate
- Loteprednol etabonate in the core is >= 80 wt% (dependent scope via later claims tightens)
- Poloxamer 407 non-covalently adsorbed to the core particle
-
Excipients and composition set
- Sodium chloride
- Glycerin
- Disodium EDTA
- Sodium citrate
- Citric acid
- Water
- pH at least 5 and <= about 7
Interpretation for scope: Claim 1 is not just “loteprednol for dry eye.” It is “loteprednol etabonate in a very specific nanoparticle formulation using poloxamer 407 noncovalently adsorbed, plus defined pH and excipient package, plus 4x/day dosing.”
Dependent claims extend composition and operational boundaries
- Claim 2 adds benzalkonium chloride.
- Claims 3-4 define concentration windows and poloxamer:steroid weight ratio.
- Claims 5-6 narrow to specific poloxamer and excipient setpoints.
- Claims 7-9 add osmolality/osmolarity constraints and drop number.
- Claims 10 adds a constraint on a loteprednol-related chemical impurity/species (a steroid-chloromethyl ester derivative threshold relative to loteprednol etabonate).
- Claims 12, 17-21 add additional structural limits:
- Core “substantially free” of a polymeric component
- Poloxamer surface density range (molecules/nm²)
- Core wt% of loteprednol etabonate tightened to >= 90 / 95 / 99 wt%
How do the specific claim limitations constrain the patent’s enforceable scope?
High-impact constraints in this claim set are the “stack” requirements. Competitors must avoid any one of the required elements in the asserted method claim, or else risk infringement.
1) Nanoparticle coating requirement: “poloxamer 407 non-covalently adsorbed”
- Claim 1 requires poloxamer 407 and that it is non-covalently adsorbed to the core.
- Dependent claims 17 and 18 set surface density ranges:
- Claim 17: >= 0.01 molecules/nm² and < 10 molecules/nm²
- Claim 18: tighter: >= 0.05 molecules/nm² and < 10 molecules/nm²
Scope effect: This is a core design anchor. A competitor using:
- a different polymer,
- poloxamer covalently attached,
- poloxamer present but not “adsorbed” (e.g., encapsulated away from the surface),
- or surface coverage outside the specified density,
may fall outside key dependent claim boundaries, though doctrine-of-equivalents questions remain for the independent claim.
2) Active concentration: “about 0.25% w/v loteprednol etabonate”
- Claim 1 fixes active at ~0.25% w/v.
- Dependent claims do not materially change that concentration.
Scope effect: A different concentration could be a meaningful design-around. However, “about” can capture a range. The precise infringement boundary typically turns on claim construction and evidence of formulation variability.
3) Core composition: loteprednol etabonate wt% in the core
- Claim 1: core contains loteprednol etabonate at >= 80 wt%
- Claims 19-21 tighten:
- >= 90 wt% (Claim 19)
- >= 95 wt% (Claim 20)
- >= 99 wt% (Claim 21)
Scope effect: If a competitor’s nanoparticle core contains a substantial polymeric or excipient fraction such that steroid content falls below the relevant wt% threshold, they may avoid dependent claims. Claim 1 still requires >=80 wt%, so only formulations that include additional core materials to push below 80 wt% are safer on the independent claim.
4) “Substantially free of a polymeric component”
- Claim 12 adds: core particle is substantially free of a polymeric component.
Scope effect: This targets formulations where the core is polymer composite rather than steroid-dominant. If a competitor uses polymeric matrices with loteprednol distributed in a polymer carrier, it can trigger non-infringement on at least this dependent limitation.
5) pH requirement: “at least 5 and less than or equal to about 7”
- Claim 1 requires pH within this window.
Scope effect: This limits buffer system choices and may require tight formulation control. Many ophthalmic buffers can fit, but a competitor selecting a different pH outside the band may avoid.
6) Excipients package and optional preservative
- Claim 1 enumerates sodium chloride, glycerin, disodium EDTA, sodium citrate, citric acid, and water.
- Claim 2 optionally adds benzalkonium chloride as a required limitation only when asserted with Claim 2 dependent.
Scope effect: Because benzalkonium chloride is optional (Claim 2), a competitor could omit it to avoid dependent Claim 2, but Claim 1 still requires the other listed buffer/tonicity components.
7) Drop dosing and frequency
- Claim 1 requires four times daily.
- Claim 9 adds: instillation of one to two drops per eye (dependent on Claim 6’s composition).
- Other dependent claims repeat “one to two drops” and link to ocular discomfort reduction.
Scope effect: If a competitor uses different dosing frequency (e.g., bid or tid), they may avoid method claims framed around “four times daily.” If the method claim is asserted as a single “administration regimen” infringement, frequency is usually material.
What is the detailed numeric formulation envelope in US 10,945,948?
Composition ratios and range chart (from dependent claims)
| Component |
Minimum |
Maximum |
Claim dependency |
| Poloxamer 407 (w/v) |
0.01% |
2% |
Claim 3 |
| Sodium chloride (w/v) |
0.1% |
1% |
Claim 3 |
| Glycerin (w/v) |
0.5% |
3% |
Claim 3 |
| Disodium EDTA (w/v) |
0.001% |
0.1% |
Claim 3 |
| Benzalkonium chloride (w/v) |
0.001% |
0.05% |
Claim 3 |
| Lotepr etabonate : poloxamer (w/w) |
1:1 |
3:1 |
Claim 4 |
| Poloxamer 407 (w/v) |
0.125% |
0.125% |
Claim 5 (fixed) |
| Sodium chloride (w/v) |
0.45% |
0.9% |
Claim 6 |
| Glycerin (w/v) |
0.6% |
0.6% |
Claim 6 (fixed) |
| Disodium EDTA (w/v) |
0.01% |
0.1% |
Claim 6 |
| Osmolality / osmolarity |
~300 mOsm/kg |
— |
Claim 7 |
| Osmolarity |
250 mOsm/L |
310 mOsm/L |
Claim 8 |
| Drops per eye |
1 |
2 |
Claim 9 |
| Core loteprednol etabonate wt% |
80% |
— |
Claim 1 |
| Core loteprednol etabonate wt% |
90% |
— |
Claim 19 |
| Core loteprednol etabonate wt% |
95% |
— |
Claim 20 |
| Core loteprednol etabonate wt% |
99% |
— |
Claim 21 |
Steroid-derivative threshold constraint
- Claim 10: sterile ophthalmic composition; includes “less than or equal to about 0.5 wt % 17α-[(ethoxycarbonyl)oxy]-11β-hydroxy-3-oxoandrosta-4-ene-17-carboxylic acid chloromethyl ester relative to the weight of the loteprednol etabonate in the ophthalmic suspension.”
Scope effect: This is a manufacturing-related impurity/species limitation that can provide a litigation lever tied to QC/analytical results. It is a meaningful barrier for competitors whose upstream synthesis yields a higher level of that species.
How strong is patent coverage for formulation variants, dosing changes, and preservative alternatives?
Best enforceability targets are method claims where the accused product is used exactly as claimed: nanoparticle coated with poloxamer 407, loteprednol concentration around 0.25% w/v, pH within 5 to ~7, with the enumerated excipient system, and four times daily dosing.
Formulation variants most likely to fall outside claim scope
- Different coating chemistry: poloxamer present but not “non-covalently adsorbed” or with a different coating approach.
- Different surface density outside the molecules/nm² bands in Claims 17-18.
- Core architecture changes: core not >=80 wt% loteprednol etabonate, or core not “substantially free” of polymeric component (Claim 12).
- Different pH outside 5-~7.
- Different concentration materially deviating from “about 0.25% w/v”.
- Different dosing regimen not “four times daily.”
- Different tonic/osmolarity: deviating from claimed osmolality/osmolarity targets can avoid dependent claims 7-8 if asserted.
Variants that may still be risky even if one element changes
- Because Claim 1 is broad on some aspects (e.g., optional benzalkonium chloride is not required), omitting BAK may avoid dependent Claim 2 but not necessarily Claim 1.
- If a competitor maintains core architecture, poloxamer adsorption, approximate concentration, pH, and 4x/day dosing, they remain exposed even if they tweak excipient levels inside or near dependent ranges.
What does US 10,945,948 imply about method-of-use infringement vs product infringement?
Key point: This is a method claim tied to administering a specific ophthalmic suspension composition. In practice, litigation strategy often pivots on:
- whether a defendant product label and actual use correspond to “four times daily” and “dry eye condition,” and
- whether the administered formulation contains the required nanoparticle and formulation features (poloxamer adsorption, concentration, pH, excipients, etc.).
The dependent “reduces ocular discomfort” claims (Claims 11, 14, 16) introduce a clinical outcome limitation as an additional asserted element when those are pursued, which can raise proof burdens on the patentee depending on how courts treat “intended result” vs functional limitation.
How does claim scope differ across the dependent claims (which ones are litigation-relevant)?
Most litigation-relevant dependent limitations
- Poloxamer surface density (Claims 17-18): quantitative and analyzable.
- Core loteprednol wt% (Claims 19-21): can be assessed by formulation composition and characterization.
- Impurity/species threshold (Claim 10): tied to analytical chemistry and manufacturing process control.
- Osmolality/osmolarity (Claims 7-8): testable.
- Specific instillation volume and frequency (Claims 9, plus Claim 1’s 4x/day): ties to administration practice and could be matched against labeling/real-world regimens.
Dependent claims with comparatively lower marginal value
- Basic excipient ranges in Claims 3 and 6 still matter but may be harder to distinguish if competitors choose formulations near the claimed envelope.
- “Ocular discomfort reduction” may be treated as a result-based limitation requiring evidence tied to clinical outcomes.
What related US patent landscape should be expected around loteprednol nanoparticle ophthalmic suspensions?
A complete landscape requires the full US prosecution file and the list of family members and citing/cited patents. That dataset is not provided here, so the only rigorous “landscape” conclusions that can be made from the claims alone are about adjacent technical clusters that typically surround this type of invention:
Adjacent IP clusters likely implicated
- Loteprednol etabonate ophthalmic formulations for dry eye or ocular inflammation (composition and method of treatment).
- Nanoparticle drug delivery for ophthalmics, including:
- steroid nanoparticle cores,
- polymer or surfactant coating layers (including poloxamers),
- noncovalent adsorption-based stabilization.
- Tonicity and buffer system claims (citrate/citric acid, sodium chloride, EDTA).
- Preservative-containing ophthalmic compositions (BAK or alternatives).
- Manufacturing impurity control claims (steriod-species thresholds).
Within those clusters, US 10,945,948’s novelty emphasis appears to be the combination of:
- loteprednol etabonate core nanoparticles with
- poloxamer 407 noncovalent adsorption at quantified surface density and defined concentration,
- delivered as a specific ophthalmic suspension with controlled pH and tonicity,
- administered four times daily for dry eye.
Which design-arounds are most plausible given the claim structure?
Composition-level design-around paths
- Replace poloxamer 407 with another surfactant or polymer, or use poloxamer in a way that is not “non-covalently adsorbed” to the nanoparticle surface.
- Engineer the nanoparticle surface density to be outside the claimed 0.01–<10 molecules/nm² or 0.05–<10 molecules/nm² depending on the claim asserted.
- Reduce the fraction of loteprednol in the core below 80 wt% (Claim 1 threshold) or below 90/95/99 wt% (dependent claim thresholds).
- Use a core that is not “substantially free” of a polymeric component.
Operational design-around paths
- Change the dosing regimen away from four times daily.
- Change drop volume away from one to two drops per eye where that limitation is asserted.
Manufacturing design-around
- Control impurities to shift the specified steroid-derivative impurity level above or below the threshold, noting Claim 10’s “less than or equal to about 0.5 wt%” constraint. Depending on manufacturing, this can be used either to avoid or to satisfy claim limits, but in infringement, it becomes an evidentiary bridge tied to defendant QC data.
Key Takeaways
- US 10,945,948 is composition-bounded: it claims dry-eye treatment via administering an eye-drop suspension at ~0.25% w/v loteprednol etabonate with poloxamer 407 noncovalently adsorbed onto loteprednol-rich nanoparticle cores.
- The nanoparticle coating and quantification are the sharpest boundaries: surface density and noncovalent adsorption language narrow enforceable scope.
- Formulation boundaries are layered: pH (5–~7), excipient set, optional BAK, tonicities (osmolality/osmolarity targets) and impurity threshold (Claim 10) support multiple claim tracks in litigation.
- Method boundaries are enforceable: the regimen is four times daily, and dependent claims tie to 1-2 drops per eye and “reduces ocular discomfort.”
- Design-arounds most directly map to single elements: change coating chemistry/surface coverage, move active concentration materially, shift pH/tonicity outside targets, alter dosing frequency, or change core composition wt%.
FAQs
1) Does US 10,945,948 cover loteprednol eye drops without nanoparticles?
No. Claim 1 requires a suspension with coated nanoparticles having a loteprednol etabonate core and poloxamer 407 noncovalently adsorbed.
2) If a competitor omits benzalkonium chloride, do they avoid infringement?
Omitting BAK avoids only Claim 2 dependent coverage; it does not remove exposure under Claim 1, which does not require BAK.
3) Can a different pH buffer system avoid the patent?
Yes, if the formulation pH falls outside pH >= 5 and <= about 7, since that pH limitation is in Claim 1.
4) What is the significance of the “0.5 wt%” steroid-derivative limit in Claim 10?
It is a formulation QC constraint tied to a specific loteprednol-related species relative to loteprednol etabonate, creating a potential analytical and manufacturing proof point.
5) Is “reduces ocular discomfort” a mandatory limitation?
It is in dependent claims (Claims 11, 14, 16). If those dependents are asserted, the outcome limitation becomes part of the infringement theory tied to the administration method.
References (APA)
- United States Patent 10,945,948.
